TABLE 1.
Baseline characteristics of Japanese patients with METex14 skipping NSCLC in VISION.
| Baseline characteristics | Japanese patients (n = 38) |
|---|---|
| Age | |
| Median, years (range) | 73 years (63–88) |
| <65 years, n (%) | 2 (5.3) |
| ≥65 years, n (%) | 36 (94.7) |
| <75 years, n (%) | 23 (60.5) |
| ≥75 years, n, (%) | 15 (39.5) |
| Sex, n (%) | |
| Male | 26 (68.4) |
| Female | 12 (31.6) |
| Smoking history, n (%) | |
| Yes | 21 (55.3) |
| No | 16 (42.1) |
| Histology, n (%) | |
| Adenocarcinoma | 29 (76.3) |
| Squamous | 2 (5.3) |
| Adenosquamous | 1 (2.6) |
| Sarcomatoid | 0 |
| Others a | 6 (15.8) |
| ECOG PS, n (%) | |
| 0 | 14 (36.8) |
| 1 | 24 (63.2) |
| Line of therapy, n (%) | |
| Treatment naïve | 18 (47.4) |
| Previously treated | 20 (52.6) |
| METex14 skipping detection, n (%) b | |
| T+ | 34 (89.5) |
| L+ | 14 (36.8) |
| Brain metastases at baseline, c n (%) | 4 (10.5) |
a
Other histology included: large cell, adenocarcinoma with sarcomatoid, NSCLC/NSCLC‐NOS, and missing/cannot classify.
b
In 10 patients, METex14 skipping was detected by both liquid and tissue biopsy.
c
Identified by IRC or investigator.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IRC, independent review; committee; L+, METex14 skipping detected in liquid biopsy; METex14, MET exon 14; NOS, not otherwise specified; T+, METex14 skipping detected in tissue biopsies.